glycine has been researched along with Liver Dysfunction in 94 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether administration of glycine, a nonessential amino acid, early after the onset of polymicrobial sepsis has any beneficial effects on hepatocellular function and the survivability of septic animals and, if so, whether the beneficial effects of glycine are associated with down-regulation of proinflammatory cytokine tumor necrosis factor-alpha production." | 9.09 | Glycine attenuates hepatocellular depression during early sepsis and reduces sepsis-induced mortality. ( Chaudry, IH; Koo, DJ; Wang, P; Yang, S, 2001) |
| "Sivelestat sodium hydrate (sivelestat) is a specific neutrophil elastase inhibitor that is effective in treating acute lung injury associated with systemic inflammatory response syndrome." | 7.80 | Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury. ( Fujimura, T; Fushida, S; Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Munesue, S; Nakagawara, H; Nakanuma, S; Ohta, T; Saito, H; Sakai, S; Tajima, H; Yamamoto, Y, 2014) |
| "We investigated the effects of a glycine-containing diet (5%) on liver injury caused by hemorrhagic shock and resuscitation in rats." | 7.71 | Dietary glycine inhibits activation of nuclear factor kappa B and prevents liver injury in hemorrhagic shock in the rat. ( Culebras, JM; González, P; González-Gallego, J; Matilla, B; Mauriz, JL, 2001) |
| "Glycine is a non-essential amino acid which is cheap, easily available and relatively non-toxic." | 6.43 | The role of glycine in hepatic ischemia-reperfusion injury. ( Davidson, BR; Habib, MM; Hodgson, HJ, 2006) |
| "Systemic complications in alcoholic pancreatitis are supposed to be aggravated by inflammatory liver damage." | 5.36 | Effects of gadolinium chloride and glycine on hepatic and pancreatic tissue damage in alcoholic pancreatitis. ( Fortunato, F; Fritz, S; Gebhard, MM; Hackert, T; Hartwig, W; Krych, R; Longerich, T; Schneider, L; Werner, J, 2010) |
| "To determine whether administration of glycine, a nonessential amino acid, early after the onset of polymicrobial sepsis has any beneficial effects on hepatocellular function and the survivability of septic animals and, if so, whether the beneficial effects of glycine are associated with down-regulation of proinflammatory cytokine tumor necrosis factor-alpha production." | 5.09 | Glycine attenuates hepatocellular depression during early sepsis and reduces sepsis-induced mortality. ( Chaudry, IH; Koo, DJ; Wang, P; Yang, S, 2001) |
| "Sivelestat sodium hydrate (sivelestat) is a specific neutrophil elastase inhibitor that is effective in treating acute lung injury associated with systemic inflammatory response syndrome." | 3.80 | Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury. ( Fujimura, T; Fushida, S; Hayashi, H; Kitagawa, H; Makino, I; Miyashita, T; Munesue, S; Nakagawara, H; Nakanuma, S; Ohta, T; Saito, H; Sakai, S; Tajima, H; Yamamoto, Y, 2014) |
| "The effect of Sivelestat, a neutrophil elastase inhibitor, on hepatic ischemia-reperfusion injury was examined in a pig hepatectomy model." | 3.74 | Protective effect of Sivelestat in a porcine hepatectomy model prepared using an intermittent Pringle method. ( Iwasaki, Y; Kubota, K; Okada, T; Sawada, T; Shimoda, M, 2008) |
| "We investigated the effects of a glycine-containing diet (5%) on liver injury caused by hemorrhagic shock and resuscitation in rats." | 3.71 | Dietary glycine inhibits activation of nuclear factor kappa B and prevents liver injury in hemorrhagic shock in the rat. ( Culebras, JM; González, P; González-Gallego, J; Matilla, B; Mauriz, JL, 2001) |
| "Eligible adults with advanced malignancies for which no further effective therapy was available received a single dose of ixazomib on day 1 of the pharmacokinetic cycle; patients with normal hepatic function, moderate hepatic impairment or severe hepatic impairment received 4 mg, 2." | 2.82 | Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment. ( Falchook, G; Fu, S; Gupta, N; Hanley, MJ; Labotka, R; Nemunaitis, J; Norris, RE; Perez, R; Qian, MG; Venkatakrishnan, K; Yang, H, 2016) |
| "Melagatran was the predominant compound in urine, accounting for 13-14% of the ximelagatran dose." | 2.71 | No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. ( Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Frison, L; Wåhlander, K, 2003) |
| "Glycine is a non-essential amino acid which is cheap, easily available and relatively non-toxic." | 2.43 | The role of glycine in hepatic ischemia-reperfusion injury. ( Davidson, BR; Habib, MM; Hodgson, HJ, 2006) |
| " Mean terminal half-life (t ½) appeared to be longer (17." | 1.43 | Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor. ( Adel, MD; Alexiev, A; Groenendaal-van de Meent, D; Krebs-Brown, A; Mateva, L; Noukens, J; Rijnders, S; Schaddelee, M, 2016) |
| "Hydrogen sulfide (H2S) is a naturally occurring gaseous transmitter, which may play important roles in normal physiology and disease." | 1.40 | Propargylglycine aggravates liver damage in LPS-treated rats: Possible relation of nitrosative stress with the inhibition of H2S formation. ( Bekpinar, S; Gurdol, F; Unlucerci, Y; Uysal, M, 2014) |
| "Systemic complications in alcoholic pancreatitis are supposed to be aggravated by inflammatory liver damage." | 1.36 | Effects of gadolinium chloride and glycine on hepatic and pancreatic tissue damage in alcoholic pancreatitis. ( Fortunato, F; Fritz, S; Gebhard, MM; Hackert, T; Hartwig, W; Krych, R; Longerich, T; Schneider, L; Werner, J, 2010) |
| "Glycine pretreatment markedly decreased transaminase release (AST, 12 hr: glycine 1292 +/- 192 U/L, control 2311 +/- 556 U/L, p < ." | 1.36 | Glycine pretreatment ameliorates liver injury after partial hepatectomy in the rat. ( Baba, HA; Benko, T; Best, J; de Groot, H; Fandrey, J; Frede, S; Gu, Y; Rauen, U; Schlaak, JF, 2010) |
| "Ischemia/reperfusion injury is mediated by various mechanisms." | 1.35 | Fundamental efforts toward the development of a therapeutic cocktail with a manifold ameliorative effect on hepatic ischemia/reperfusion injury. ( Backhaus, J; Büchler, MW; Flechtenmacher, C; Gebhard, MM; Kincius, M; Liang, R; Schemmer, P; Schindler, G; Zorn, M, 2009) |
| "Sivelestat pretreatment inhibited the activation of nuclear factor (NF) kappaB, caspase 3 and 8 activities, and cytochrome c release." | 1.34 | Neutrophil elastase inhibitor prevents endotoxin-induced liver injury following experimental partial hepatectomy. ( Kwon, AH; Qiu, Z, 2007) |
| "PABA is well absorbed by the gastrointestinal tract and acetylated and conjugated in the liver to glycine before being excreted." | 1.29 | Preliminary assessment of glycine conjugation of para-aminobenzoic acid as a quantitative test of liver function. ( Barr, SB; Duffy, LF; Kerzner, B; Seeff, L; Soldin, SJ, 1995) |
| "The bilirubin clearance was impaired to 30-50% of the normal value in most cases of hepatobiliary disease and also in primary haemolysis." | 1.28 | The origins and kinetics of bilirubin in dogs with hepatobiliary and haemolytic diseases. ( Fevery, J; Rothuizen, J; van den Brom, WE, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 47 (50.00) | 18.7374 |
| 1990's | 13 (13.83) | 18.2507 |
| 2000's | 18 (19.15) | 29.6817 |
| 2010's | 11 (11.70) | 24.3611 |
| 2020's | 5 (5.32) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, T | 1 |
| Zhou, K | 1 |
| Sun, T | 1 |
| Sang, C | 1 |
| Jia, W | 1 |
| Xie, G | 1 |
| Mahar, KM | 1 |
| Shaddinger, BC | 1 |
| Ramanjineyulu, B | 1 |
| Andrews, S | 1 |
| Caltabiano, S | 1 |
| Lindsay, AC | 1 |
| Cobitz, AR | 1 |
| Rieg, CEH | 1 |
| Cattani, D | 1 |
| Naspolini, NF | 1 |
| Cenci, VH | 1 |
| de Liz Oliveira Cavalli, VL | 1 |
| Jacques, AV | 1 |
| Nascimento, MVPDS | 1 |
| Dalmarco, EM | 1 |
| De Moraes, ACR | 1 |
| Santos-Silva, MC | 1 |
| Silva, FRMB | 1 |
| Parisotto, EB | 1 |
| Zamoner, A | 1 |
| Tabori, H | 1 |
| Schneider, J | 1 |
| Lüth, S | 1 |
| Zagoya, C | 1 |
| Barucha, A | 1 |
| Lehmann, T | 1 |
| Kauf, E | 1 |
| Barth, A | 1 |
| Mainz, JG | 1 |
| Chavan, A | 1 |
| Burke, L | 1 |
| Sawant, R | 1 |
| Navarro-Gonzales, P | 1 |
| Vargo, D | 1 |
| Paulson, SK | 1 |
| Sakai, S | 1 |
| Tajima, H | 1 |
| Miyashita, T | 1 |
| Nakanuma, S | 1 |
| Makino, I | 1 |
| Hayashi, H | 1 |
| Nakagawara, H | 1 |
| Kitagawa, H | 1 |
| Fushida, S | 1 |
| Fujimura, T | 1 |
| Saito, H | 1 |
| Munesue, S | 1 |
| Yamamoto, Y | 1 |
| Ohta, T | 1 |
| Bekpinar, S | 1 |
| Unlucerci, Y | 1 |
| Uysal, M | 1 |
| Gurdol, F | 1 |
| Luo, JX | 1 |
| Zhang, Y | 1 |
| Hu, XY | 1 |
| Chen, G | 1 |
| Liu, XY | 1 |
| Nie, HM | 1 |
| Liu, JL | 1 |
| Wen, DC | 1 |
| Gupta, N | 1 |
| Hanley, MJ | 1 |
| Venkatakrishnan, K | 1 |
| Perez, R | 1 |
| Norris, RE | 1 |
| Nemunaitis, J | 1 |
| Yang, H | 1 |
| Qian, MG | 1 |
| Falchook, G | 1 |
| Labotka, R | 1 |
| Fu, S | 1 |
| Groenendaal-van de Meent, D | 1 |
| Adel, MD | 1 |
| Noukens, J | 1 |
| Rijnders, S | 1 |
| Krebs-Brown, A | 1 |
| Mateva, L | 1 |
| Alexiev, A | 1 |
| Schaddelee, M | 1 |
| Osna, NA | 1 |
| Feng, D | 1 |
| Ganesan, M | 1 |
| Maillacheruvu, PF | 1 |
| Orlicky, DJ | 1 |
| French, SW | 1 |
| Tuma, DJ | 1 |
| Kharbanda, KK | 1 |
| Dos Santos, APR | 1 |
| Rocha, TL | 1 |
| Borges, CL | 1 |
| Bailão, AM | 1 |
| de Almeida Soares, CM | 1 |
| de Sabóia-Morais, SMT | 1 |
| Xu, FL | 1 |
| You, HB | 1 |
| Li, XH | 1 |
| Chen, XF | 1 |
| Liu, ZJ | 1 |
| Gong, JP | 1 |
| Froh, M | 1 |
| Zhong, Z | 2 |
| Walbrun, P | 1 |
| Lehnert, M | 1 |
| Netter, S | 1 |
| Wiest, R | 1 |
| Conzelmann, L | 1 |
| Gabele, E | 1 |
| Hellerbrand, C | 1 |
| Scholmerich, J | 1 |
| Thurman, RG | 2 |
| Schindler, G | 1 |
| Kincius, M | 1 |
| Liang, R | 1 |
| Backhaus, J | 1 |
| Zorn, M | 1 |
| Flechtenmacher, C | 1 |
| Gebhard, MM | 2 |
| Büchler, MW | 1 |
| Schemmer, P | 1 |
| Schneider, L | 1 |
| Hackert, T | 1 |
| Longerich, T | 1 |
| Hartwig, W | 1 |
| Fritz, S | 1 |
| Krych, R | 1 |
| Fortunato, F | 1 |
| Werner, J | 1 |
| Pak, S | 1 |
| Kondo, T | 1 |
| Nakano, Y | 1 |
| Murata, S | 1 |
| Fukunaga, K | 1 |
| Oda, T | 2 |
| Sasaki, R | 1 |
| Ohkohchi, N | 1 |
| Benko, T | 1 |
| Frede, S | 1 |
| Gu, Y | 1 |
| Best, J | 1 |
| Baba, HA | 1 |
| Schlaak, JF | 1 |
| de Groot, H | 1 |
| Fandrey, J | 1 |
| Rauen, U | 1 |
| de Graaf, W | 1 |
| van Lienden, KP | 1 |
| van den Esschert, JW | 1 |
| Bennink, RJ | 1 |
| van Gulik, TM | 1 |
| Ishii, K | 2 |
| Ito, Y | 1 |
| Katagiri, H | 1 |
| Matsumoto, Y | 1 |
| Kakita, A | 1 |
| Majima, M | 1 |
| Wåhlander, K | 1 |
| Eriksson-Lepkowska, M | 1 |
| Frison, L | 1 |
| Fager, G | 1 |
| Eriksson, UG | 1 |
| Bruck, R | 1 |
| Wardi, J | 1 |
| Aeed, H | 1 |
| Avni, Y | 1 |
| Shirin, H | 1 |
| Avinoach, I | 1 |
| Shahmurov, M | 1 |
| Hershkoviz, R | 1 |
| VISTOLI, G | 1 |
| ORLANDO, E | 1 |
| DEL NINNO, R | 1 |
| MORGANO, G | 2 |
| FAZIO, B | 2 |
| BALESTRERI, R | 2 |
| YAMANAKA, M | 1 |
| BRAUN, GA | 1 |
| MARSH, JB | 1 |
| DRABKIN, DL | 1 |
| GUIDOTTI, GG | 1 |
| ROSSI, CB | 1 |
| RAGNOTTI, G | 1 |
| RATNER, AC | 1 |
| DOBSON, RL | 1 |
| BERLIN, NI | 1 |
| CHISOLM, JJ | 1 |
| MONDEN, M | 1 |
| GEORGI, F | 1 |
| BEUTHIEN, A | 1 |
| KAWAKAMI, T | 1 |
| TOKUDA, R | 1 |
| Habib, MM | 1 |
| Hodgson, HJ | 2 |
| Davidson, BR | 1 |
| Kwon, AH | 1 |
| Qiu, Z | 1 |
| Kansoul, HA | 1 |
| Axelsson, R | 1 |
| Yamamoto, S | 1 |
| Savicheva, I | 1 |
| Aspelin, P | 1 |
| Ericzon, BG | 1 |
| Gjertsen, H | 1 |
| Hidaka, I | 1 |
| Hino, K | 1 |
| Korenaga, M | 1 |
| Gondo, T | 1 |
| Nishina, S | 1 |
| Ando, M | 1 |
| Okuda, M | 1 |
| Sakaida, I | 1 |
| Shimoda, M | 1 |
| Iwasaki, Y | 1 |
| Okada, T | 1 |
| Sawada, T | 1 |
| Kubota, K | 1 |
| Linnet, K | 1 |
| Andersen, JR | 1 |
| Klingensmith, WC | 2 |
| Fritzberg, AR | 1 |
| Spitzer, VM | 1 |
| Kuni, CC | 1 |
| Williamson, MR | 1 |
| Gerhold, JP | 1 |
| Bonkowsky, HL | 1 |
| Schady, W | 1 |
| Kamada, S | 1 |
| Maeda, M | 1 |
| Tsuji, A | 1 |
| Lever, M | 1 |
| Sizeland, PC | 1 |
| Bason, LM | 1 |
| Hayman, CM | 1 |
| Robson, RA | 1 |
| Chambers, ST | 1 |
| Moskowitz, H | 1 |
| Spencer, RP | 1 |
| Shapiro, HR | 1 |
| Karimeddini, MK | 1 |
| Boulahdour, H | 1 |
| Cherqui, D | 1 |
| Charlotte, F | 1 |
| Rahmouni, A | 1 |
| Dhumeaux, D | 1 |
| Zafrani, ES | 1 |
| Meignan, M | 1 |
| Donovan, JM | 1 |
| Yousef, IM | 1 |
| Carey, MC | 1 |
| Duffy, LF | 1 |
| Kerzner, B | 1 |
| Seeff, L | 1 |
| Barr, SB | 1 |
| Soldin, SJ | 2 |
| Furuya, KN | 1 |
| Durie, PR | 1 |
| Roberts, EA | 1 |
| Verjee, Z | 1 |
| Yung-Jato, L | 1 |
| Giesbrecht, E | 1 |
| Ellis, L | 1 |
| al-Nahhas, AM | 1 |
| Kingsnorth, A | 1 |
| Balon, HR | 1 |
| Fink-Bennett, DM | 1 |
| Brill, DR | 1 |
| Fig, LM | 1 |
| Freitas, JE | 1 |
| Krishnamurthy, GT | 2 |
| Royal, HD | 1 |
| Kudoh, A | 1 |
| Kudoh, E | 1 |
| Ishihara, H | 1 |
| Matsuki, A | 1 |
| Forbes, SJ | 1 |
| Themis, M | 1 |
| Alison, MR | 1 |
| Shiota, A | 1 |
| Kobayashi, T | 1 |
| Coutelle, C | 1 |
| Yang, S | 1 |
| Koo, DJ | 1 |
| Chaudry, IH | 1 |
| Wang, P | 1 |
| Sun, Y | 1 |
| Liu, B | 1 |
| Wan, J | 1 |
| Xu, H | 1 |
| Mauriz, JL | 1 |
| Matilla, B | 1 |
| Culebras, JM | 1 |
| González, P | 1 |
| González-Gallego, J | 1 |
| Li, X | 1 |
| Yamashina, S | 1 |
| von Frankenberg, M | 1 |
| Enomoto, N | 1 |
| Ikejima, K | 1 |
| Kolinsky, M | 1 |
| Raleigh, JA | 1 |
| Foster, JA | 1 |
| Ramsden, WH | 1 |
| Conway, SP | 1 |
| Taylor, JM | 1 |
| Etherington, C | 1 |
| Bilska, A | 1 |
| Włodek, L | 1 |
| Drozdz, H | 1 |
| Westergaard, H | 1 |
| Rothuizen, J | 1 |
| van den Brom, WE | 1 |
| Fevery, J | 1 |
| Bosman, DK | 1 |
| Deutz, NE | 1 |
| Maas, MA | 1 |
| van Eijk, HM | 1 |
| Smit, JJ | 1 |
| de Haan, JG | 1 |
| Chamuleau, RA | 1 |
| Talbot, AR | 1 |
| Shiaw, MH | 1 |
| Huang, JS | 1 |
| Yang, SF | 1 |
| Goo, TS | 1 |
| Wang, SH | 1 |
| Chen, CL | 1 |
| Sanford, TR | 1 |
| Doo, E | 1 |
| Eklem, MJ | 1 |
| Gilbert, S | 1 |
| Brown, PH | 1 |
| Watanabe, A | 1 |
| Shiota, T | 1 |
| Takei, N | 1 |
| Nagashima, H | 1 |
| de Verneuil, H | 1 |
| Hansen, J | 1 |
| Picat, C | 1 |
| Grandchamp, B | 1 |
| Kushner, J | 1 |
| Roberts, A | 1 |
| Elder, G | 1 |
| Nordmann, Y | 1 |
| Sugiyama, K | 1 |
| Okuyama, S | 1 |
| Imoto, M | 1 |
| Okumura, K | 1 |
| Takagi, K | 1 |
| Satake, T | 1 |
| Altschule, MD | 1 |
| Hegedus, ZL | 1 |
| Discombe, G | 1 |
| Lund, S | 1 |
| Richter, J | 1 |
| Ohlen, J | 1 |
| Sherr, HP | 1 |
| Nair, PP | 1 |
| White, JJ | 1 |
| Banwell, JG | 1 |
| Lockwood, DH | 1 |
| Hardison, WG | 1 |
| Pappo, A | 1 |
| James, OF | 1 |
| Agnew, JE | 1 |
| Bouchier, IA | 1 |
| Imaizumi, K | 1 |
| Haije, WG | 1 |
| Madden, JW | 1 |
| Chvapil, M | 1 |
| Carlson, EC | 1 |
| Ryan, JN | 1 |
| Buxton, BH | 1 |
| Stewart, DA | 1 |
| Murray-Lyon, IM | 1 |
| Curzon, G | 1 |
| Williams, R | 1 |
| Panfil, B | 1 |
| Szczeklik, A | 1 |
| Szewczuk, A | 1 |
| Nowosad, H | 1 |
| Kolaczkowska, B | 1 |
| Plomteux, G | 1 |
| Heusghem, C | 1 |
| Pedersen, VF | 1 |
| Walls, WD | 1 |
| Losowsky, MS | 1 |
| Grannis, GF | 1 |
| Neale, G | 1 |
| Lewis, B | 1 |
| Weaver, V | 1 |
| Panveliwalla, D | 1 |
| Doss, M | 2 |
| Nawrocki, P | 2 |
| Schmidt, A | 2 |
| Strohmeyer, G | 2 |
| Egbring, R | 2 |
| Schimpff, G | 1 |
| Dölle, W | 1 |
| Korb, G | 2 |
| Look, D | 1 |
| Henning, H | 1 |
| Lüders, CJ | 1 |
| Krien, E | 1 |
| Zeitler, G | 1 |
| Luchmann, A | 1 |
| Robinson, SH | 1 |
| Brunner, G | 1 |
| Sommer, J | 1 |
| Kattermann, R | 1 |
| Tung, JS | 1 |
| Ostwald, R | 1 |
| Ronchi, F | 1 |
| Guacci, L | 1 |
| Abbolito, A | 1 |
| Bufano, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1, Open-label, Non-randomized, Parallel Group, Single-dose Adaptive Study in Adults With Hepatic Impairment and Matched, Healthy Control Participants With Normal Hepatic Function[NCT03223337] | Phase 1 | 37 participants (Actual) | Interventional | 2017-07-24 | Completed | ||
| Predictive Value of Hepato Biliary Scintigraphy to Assess the Risk of Postoperative Liver Failure Hepatectomies Stretches of 4 or More Segments on Non-cirrhotic Liver[NCT02753517] | 400 participants (Anticipated) | Interventional | 2015-12-08 | Recruiting | |||
| Is It Possible To Predict PHLF? - Retrospective Analysis of Gadoxetate MRI Prior To Major Liver Resection[NCT04692259] | 200 participants (Anticipated) | Interventional | 2020-12-29 | Recruiting | |||
| [NCT00005306] | 0 participants | Observational | 1988-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
| Intervention | Hours* International units per liter (Mean) |
|---|---|
| Part 1: Moderate Hepatic Impairment Participants | 1262.3724 |
| Part 1: Healthy Participants | 697.7140 |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points. Pharmacodynamic Population comprised of all participants in the Safety Population who had at least one pharmacodynamic assessment. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
| Intervention | International units per liter (Mean) |
|---|---|
| Part 1: Moderate Hepatic Impairment Participants | 48.898 |
| Part 1: Healthy Participants | 28.391 |
Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine. (NCT03223337)
Timeframe: Up to Day 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 1: Moderate Hepatic Impairment Participants | 0 |
| Part 1: Healthy Participants | 0 |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
| Intervention | Hours (Median) |
|---|---|
| Part 1: Moderate Hepatic Impairment Participants | 10.0 |
| Part 1: Healthy Participants | 10.0 |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
| Intervention | Hours* International units per liter (Mean) |
|---|---|
| Part 2: Mild Hepatic Impairment Participants | 1258.6211 |
| Part 2: Healthy Participants | 1061.7549 |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
| Intervention | International units per liter (Mean) |
|---|---|
| Part 2: Mild Hepatic Impairment Participants | 43.933 |
| Part 2: Healthy Participants | 45.871 |
Urine samples were collected at indicated time points for the analysis of urine parameters including specific gravity and Potential of hydrogen (pH) of urine, presence of glucose, protein, blood, ketones, bilirubin, urobilinogen, nitrite, and leukocyte esterase in urine. (NCT03223337)
Timeframe: Up to Day 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Part 2: Mild Hepatic Impairment Participants | 0 |
| Part 2: Healthy Participants | 0 |
Venous blood samples were collected for measurement of plasma EPO at the indicated time points following administration of GSK1278863. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, and 48 hours post-dose
| Intervention | Hours (Median) |
|---|---|
| Part 2: Mild Hepatic Impairment Participants | 10.0 |
| Part 2: Healthy Participants | 10.0 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Hours (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 1: Healthy Participants | 4.4054 | 5.6415 | 3.6385 | 2.7314 | NA | 3.2641 | 3.9414 |
| Part 1: Moderate Hepatic Impairment Participants | 3.9867 | 4.1830 | 2.6559 | 3.1966 | NA | 3.1287 | 3.9432 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Pharmacokinetic Population comprised of all participants in the Safety Population for whom a pharmacokinetic sample was obtained and analyzed. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Hour*nanogram per milliliter (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 1: Healthy Participants | 148.3225 | 47.1340 | 28.9896 | 11.2658 | NA | 20.9224 | 39.6044 |
| Part 1: Moderate Hepatic Impairment Participants | 296.2407 | 77.6352 | 47.5557 | 16.8212 | NA | 33.9398 | 52.0606 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Hour*nanogram per milliliter (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 1: Healthy Participants | 148.2504 | 46.9368 | 28.7930 | 11.0208 | NA | 20.8451 | 39.4939 |
| Part 1: Moderate Hepatic Impairment Participants | 296.1035 | 77.4861 | 47.2803 | 16.7177 | NA | 33.8516 | 51.9052 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Nanogram per milliliter (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 1: Healthy Participants | 70.607 | 10.199 | 8.025 | 2.245 | NA | 4.672 | 7.120 |
| Part 1: Moderate Hepatic Impairment Participants | 139.705 | 13.046 | 10.022 | 2.650 | NA | 5.946 | 7.411 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. Safety Population comprised of all participants who received at least one dose of study medication. (NCT03223337)
Timeframe: Up to 16 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any SAE | Any AE | |
| Part 1: Healthy Participants | 0 | 2 |
| Part 1: Moderate Hepatic Impairment Participants | 0 | 1 |
Blood samples were collected for analysis of following parameters. PCI ranges were <30g/L (albumin), <2 or >2.75 millimoles/L(mmol/L) (calcium), <3 or >9mmol/L(glucose), >=2 times Upper limit of Normal(ULN) units/L(U/L) (alanine aminotransferase [ALT]), >=2 times ULN U/L (alkaline phosphatase), >=2 times ULN U/L(aspartate aminotransferase [AST]), >=1.5 times ULN micromoles/L (µmol/L)(bilirubin), <3 or >5.5mmol/L(potassium), and <130 or >150mmol/L(sodium). Participants were counted in worst case category that their value changes to (low,within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment. (NCT03223337)
Timeframe: Baseline (Screening) and up to Day 16
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT ; To Low | ALT;To within Range or No Change | ALT; To High | Albumin; To Low | Albumin; To within Range or No Change | Albumin; To High | Alkaline Phosphatase; To Low | Alkaline Phosphatase; To within Range or No Change | Alkaline Phosphatase; To High | AST; To Low | AST;To within Range or No Change | AST; To High | Bilirubin; To Low | Bilirubin; To within Range or No Change | Bilirubin; To High | Calcium; To Low | Calcium; To within Range or No Change | Calcium; To High | Glucose; To Low | Glucose; To within Range or No Change | Glucose; To High | Potassium; To Low | Potassium; To within Range or No Change | Potassium; To High | Sodium; To Low | Sodium; To within Range or No Change | Sodium; To High | |
| Part 1: Healthy Participants | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 |
| Part 1: Moderate Hepatic Impairment Participants | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 6 | 2 | 0 | 8 | 0 | 1 | 7 | 0 |
"Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were <0.075 or >0.54 proportion of red blood cells in blood for hematocrit, <25 or >180 grams per liter (g/L) for hemoglobin, <3 or >20 x10^9 cells per liter (cells/L) for leukocytes, <0.8 x10^9 cells/L for lymphocytes, <1.5 x10^9 cells/L for neutrophils, and <100 or >550 x10^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (example given [e.g.], High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment." (NCT03223337)
Timeframe: Baseline (Screening) and up to Day 16
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hematocrit; To Low | Hematocrit; To within Range or No Change | Hematocrit; To High | Hemoglobin; To Low | Hemoglobin; To within Range or No Change | Hemoglobin; To High | Leukocytes; To Low | Leukocytes; To within Range or No Change | Leukocytes; To High | Lymphocytes; To Low | Lymphocytes; To within Range or No Change | Lymphocytes; To High | Neutrophils; To Low | Neutrophils; To within Range or No Change | Neutrophils; To High | Platelets; To Low | Platelets; To within Range or No Change | Platelets; To High | |
| Part 1: Healthy Participants | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 |
| Part 1: Moderate Hepatic Impairment Participants | 0 | 8 | 0 | 0 | 8 | 0 | 1 | 7 | 0 | 0 | 8 | 0 | 0 | 8 | 0 | 0 | 8 | 0 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Percentage of AUCex (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 1: Healthy Participants | 0.0486 | 0.4176 | 0.6763 | 2.1559 | NA | 0.3689 | 0.2787 |
| Part 1: Moderate Hepatic Impairment Participants | 0.0463 | 0.1919 | 0.5756 | 0.6147 | NA | 0.2598 | 0.2983 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Hours (Median) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 1: Healthy Participants | 2.00 | 3.50 | 3.00 | 4.00 | NA | 3.50 | 4.00 |
| Part 1: Moderate Hepatic Impairment Participants | 1.50 | 3.00 | 3.00 | 3.50 | NA | 3.50 | 4.00 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: 3 hours, 12 hours and 24 hours post-dose
| Intervention | Nanograms per milliliter (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSK1278863; 3 hours | GSK1278863; 12 hours | GSK1278863; 24 hours | GSK2391220 (M2); 3 hours | GSK2391220 (M2); 12 hours | GSK2391220 (M2); 24 hours | GSK2487818 (M4); 3 hours | GSK2487818 (M4); 12 hours | GSK2487818 (M4); 24 hours | GSK2506102 (M5); 3 hours | GSK2506102 (M5); 12 hours | GSK2506102 (M5); 24 hours | GSK2506104 (M3); 3 hours | GSK2506104 (M3); 12 hours | GSK2506104 (M3); 24 hours | GSK2531398 (M6); 3 hours | GSK2531398 (M6); 12 hours | GSK2531398 (M6); 24 hours | GSK2531401 (M13); 3 hours | GSK2531401 (M13); 12 hours | GSK2531401 (M13); 24 hours | |
| Part 1: Healthy Participants | 0.11076 | NA | NA | 2.85875 | 0.22463 | 0.00963 | 1.86813 | 0.04769 | NA | 0.43175 | 0.04143 | NA | 2.57000 | 0.23938 | 0.00829 | 0.89338 | 0.06548 | NA | 2.03738 | 0.32075 | 0.01053 |
| Part 1: Moderate Hepatic Impairment Participants | 0.27989 | NA | NA | 4.47750 | 0.76525 | 0.06460 | 3.24463 | 0.29301 | 0.01201 | 0.64588 | 0.13024 | 0.00923 | 3.86250 | 0.71075 | 0.06315 | 1.42725 | 0.22973 | 0.01470 | 2.25375 | 0.63125 | 0.07580 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818, GSK2506102, GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration. (NCT03223337)
Timeframe: 3 hours, 12 hours and 24 hours post-dose
| Intervention | Percentage of unbound drug in plasma (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSK1278863; 3 hours; n=8, 8 | GSK1278863; 12 hours; n=8, 8 | GSK1278863; 24 hours; n=8,8 | GSK2391220 (M2); 3 hours; n=8,8 | GSK2391220 (M2); 12 hours; n=8,8 | GSK2391220 (M2); 24 hours; n=4,2 | GSK2487818 (M4); 3 hours; n=8,8 | GSK2487818 (M4); 12 hours; n=8,7 | GSK2487818 (M4); 24 hours; n=2,8 | GSK2506102 (M5); 3 hours; n=8, 8 | GSK2506102 (M5); 12 hours; n=8, 6 | GSK2506102 (M5); 24 hours; n=1, 8 | GSK2506104 (M3); 3 hours; n=8, 8 | GSK2506104 (M3); 12 hours; n=8, 8 | GSK2506104 (M3); 24 hours; n=8, 8 | GSK2531398 (M6); 3 hours; n=8, 8 | GSK2531398 (M6); 12 hours; n=8, 8 | GSK2531398 (M6); 24 hours; n=2, 8 | GSK2531401 (M13); 3 hours; n=8, 8 | GSK2531401 (M13); 12 hours; n=8, 8 | GSK2531401 (M13); 24 hours; n=6, 2 | |
| Part 1: Healthy Participants | 0.0028 | NA | NA | 0.3495 | 0.3355 | 0.3902 | 0.2925 | 0.2402 | NA | 0.2441 | 0.2335 | NA | NA | NA | NA | 0.2461 | 0.2295 | NA | 0.3844 | 0.3565 | 0.3716 |
| Part 1: Moderate Hepatic Impairment Participants | 0.0034 | NA | NA | 0.3379 | 0.3540 | 0.3861 | 0.3080 | 0.3071 | 0.3508 | 0.2565 | 0.2517 | 0.2723 | NA | NA | NA | 0.2469 | 0.2550 | 0.3005 | 0.3519 | 0.3771 | 0.3817 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2) , GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Hour*nanogram per milliliter (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 2: Healthy Participants | 205.7559 | 47.1647 | 31.7637 | 11.3374 | 50.1154 | 21.0066 | 31.9797 |
| Part 2: Mild Hepatic Impairment Participants | 299.8773 | 91.3799 | 63.6211 | 19.4020 | 91.7692 | 41.4666 | 46.7001 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Hour*nanogram per milliliter (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 2: Healthy Participants | 205.6322 | 46.7771 | 31.4750 | 11.1555 | 49.7669 | 20.8080 | 31.8113 |
| Part 2: Mild Hepatic Impairment Participants | 299.5322 | 91.1105 | 63.4564 | 19.3023 | 91.5334 | 41.3456 | 46.5914 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), and GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Nanogram per milliliter (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 2: Healthy Participants | 112.142 | 8.846 | 7.723 | 1.975 | 8.926 | 4.010 | 5.081 |
| Part 2: Mild Hepatic Impairment Participants | 113.232 | 15.792 | 13.614 | 3.241 | 15.475 | 7.333 | 6.791 |
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that, at any dose that results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly/birth defect or any other situation as per Medical or scientific judgment. (NCT03223337)
Timeframe: Up to 16 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Any SAE | Any AE | |
| Part 2: Healthy Participants | 0 | 0 |
| Part 2: Mild Hepatic Impairment Participants | 0 | 0 |
Blood samples were collected for analysis of following parameters. PCI ranges were <30g/L (albumin), <2 or >2.75 mmol/L (calcium), <3 or >9mmol/L (glucose), >=2 times ULN U/L (ALT), >=2 times ULN U/L (alkaline phosphatase), >=2 times ULN U/L (AST), >=1.5 times ULN µmol/L (bilirubin), <3 or >5.5 mmol/L (potassium), and <130 or >150 mmol/L (sodium). Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed To Low and To High, so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment. (NCT03223337)
Timeframe: Baseline (Screening) and up to Day 16
| Intervention | Participants (Count of Participants) | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALT ; To Low | ALT;To within Range or No Change | ALT ; To High | Albumin; To Low | Albumin; To within Range or No Change | Albumin; To High | Alkaline Phosphatase; To Low | Alkaline Phosphatase; To within Range or No Change | Alkaline Phosphatase; To High | AST; To Low | AST;To within Range or No Change | AST; To High | Bilirubin; To Low | Bilirubin; To within Range or No Change | Bilirubin; To High | Calcium; To Low | Calcium; To within Range or No Change | Calcium; To High | Glucose; To Low | Glucose; To within Range or No Change | Glucose; To High | Potassium; To Low | Potassium; To within Range or No Change | Potassium; To High | Sodium; To Low | Sodium; To within Range or No Change | Sodium; To High | |
| Part 2: Healthy Participants | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 |
| Part 2: Mild Hepatic Impairment Participants | 0 | 12 | 0 | 0 | 12 | 0 | 0 | 12 | 0 | 0 | 12 | 0 | 0 | 12 | 0 | 0 | 12 | 0 | 0 | 10 | 2 | 0 | 12 | 0 | 0 | 12 | 0 |
"Blood samples were collected for analysis of hematocrit, hemoglobin, leukocytes, lymphocytes, neutrophils and platelets. PCI ranges were <0.075 or >0.54 proportion of red blood cells in blood for hematocrit, <25 or >180 g/L for hemoglobin, <3 or >20 x10^9 cells/L for leukocytes, <0.8 x10^9 cells/L for lymphocytes, <1.5 x10^9 cells/L for neutrophils, and <100 or >550 x10^9 cells/L for platelet. Participants were counted in worst case category that their value changes to (low, within range or no change or high), unless there is no change in their category. Participants whose laboratory value category was unchanged (e.g., High to High), or whose value became within range, were recorded in To within Range or No Change category. Participants were counted twice if the participant has values that changed 'To Low' and 'To High', so the percentages may not add to 100%. Baseline is defined as latest non-missing scheduled pre-dose assessment." (NCT03223337)
Timeframe: Baseline (Screening) and up to Day 16
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hematocrit; To Low | Hematocrit; To within Range or No Change | Hematocrit; To High | Hemoglobin; To Low | Hemoglobin; To within Range or No Change | Hemoglobin; To High | Leukocytes; To Low | Leukocytes; To within Range or No Change | Leukocytes; To High | Lymphocytes; To Low | Lymphocytes; To within Range or No Change | Lymphocytes; To High | Neutrophils; To Low | Neutrophils; To within Range or No Change | Neutrophils; To High | Platelets; To Low | Platelets; To within Range or No Change | Platelets; To High | |
| Part 2: Healthy Participants | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 | 0 | 9 | 0 |
| Part 2: Mild Hepatic Impairment Participants | 0 | 12 | 0 | 0 | 12 | 0 | 0 | 12 | 0 | 1 | 11 | 0 | 0 | 12 | 0 | 0 | 12 | 0 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Percentage of AUCex (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 2: Healthy Participants | 0.0601 | 0.8105 | 0.9054 | 1.5924 | 0.6875 | 0.9412 | 0.5256 |
| Part 2: Mild Hepatic Impairment Participants | 0.1148 | 0.2943 | 0.2584 | 0.5138 | 0.2565 | 0.2915 | 0.2327 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Hours (Geometric Mean) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 2: Healthy Participants | 4.2792 | 4.7439 | 3.0578 | 3.3108 | 4.4967 | 2.9947 | 3.5510 |
| Part 2: Mild Hepatic Impairment Participants | 4.5251 | 4.8118 | 4.1059 | 3.4087 | 4.6675 | 3.8096 | 4.2869 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: Pre-dose, 30 minutes, 1 hour, 1 hour 30 minutes, 2 hours, 3 hours, 4 hours, 6 hours, 8 hours, 10 hours, 12 hours, 24 hours, 36 hours, 48 hours post-dose
| Intervention | Hours (Median) | ||||||
|---|---|---|---|---|---|---|---|
| GSK1278863 | GSK2391220 (M2) | GSK2487818 (M4) | GSK2506102 (M5) | GSK2506104 (M3) | GSK2531398 (M6) | GSK2531401 (M13) | |
| Part 2: Healthy Participants | 1.50 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 4.00 |
| Part 2: Mild Hepatic Impairment Participants | 1.50 | 3.00 | 3.00 | 3.50 | 3.50 | 3.00 | 4.00 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites; GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13). Pharmacokinetic parameters were determined using standard non-compartmental methods. (NCT03223337)
Timeframe: 3 hours, 12 hours and 24 hours post-dose
| Intervention | Nanograms per milliliter (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSK1278863; 3 hours; n=6, 6 | GSK1278863; 12 hours; n=7, 6 | GSK1278863; 24 hours; n=7, 6 | GSK2391220 (M2); 3 hours; n=8, 7 | GSK2391220 (M2); 12 hours; n=8, 7 | GSK2391220 (M2); 24 hours; n=8, 7 | GSK2487818 (M4); 3 hours; n=8,7 | GSK2487818 (M4); 12 hours; n=8,7 | GSK2487818 (M4); 24 hours; n=8,7 | GSK2506102 (M5); 3 hours; n=8,7 | GSK2506102 (M5); 12 hours; n=8,7 | GSK2506102 (M5); 24 hours; n=8,7 | GSK2506104 (M3); 3 hours; n=8,7 | GSK2506104 (M3); 12 hours; n=8,7 | GSK2506104 (M3); 24 hours; n=8,7 | GSK2531398 (M6); 3 hours; n=8,7 | GSK2531398 (M6); 12 hours; n=8,7 | GSK2531398 (M6); 24 hours; n=8,7 | GSK2531401 (M13); 3 hours; n=8,7 | GSK2531401 (M13); 12 hours; n=8,7 | GSK2531401 (M13); 24 hours; n=8,7 | |
| Part 2: Healthy Participants | 0.15692 | 0.01527 | NA | 2.13700 | 0.24371 | NA | 1.57633 | 0.07793 | 0.00454 | 0.31091 | 0.04796 | NA | 1.94271 | 0.27014 | 0.00819 | 0.73530 | 0.07879 | NA | 1.26771 | 0.29429 | 0.00454 |
| Part 2: Mild Hepatic Impairment Participants | 1.24213 | 0.04343 | NA | 5.32625 | 0.81263 | 0.30654 | 3.91375 | 0.40141 | 0.00839 | 0.78213 | 0.25856 | NA | 4.68625 | 0.75350 | 0.04093 | 1.86763 | 0.34200 | NA | 2.47825 | 0.75363 | 0.29830 |
Blood samples were collected at indicated time points for pharmacokinetic analysis of GSK1278863 and its metabolites (GSK2391220 (M2), GSK2506104 (M3), GSK2487818 (M4), GSK2506102 (M5), GSK2531398 (M6), GSK2531401 (M13)). Pharmacokinetic parameters were determined using standard non-compartmental methods. Unbound fraction is the percentage of unbound drug in plasma calculated as unbound concentration divided by total concentration. (NCT03223337)
Timeframe: 3 hours, 12 hours and 24 hours post-dose
| Intervention | Percentage of unbound drug in plasma (Mean) | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GSK1278863; 3 hours; n=6, 6 | GSK1278863; 12 hours; n=1, 1 | GSK1278863; 24 hours; n=8,7 | GSK2391220 (M2); 3 hours; n=8, 7 | GSK2391220 (M2); 12 hours; n=7, 7 | GSK2391220 (M2); 24 hours; n=5, 7 | GSK2487818 (M4); 3 hours; n=8, 7 | GSK2487818 (M4); 12 hours; n=7, 7 | GSK2487818 (M4); 24 hours; n=2, 1 | GSK2506102 (M5); 3 hours; n=8, 6 | GSK2506102 (M5); 12 hours; n=7, 6 | GSK2506102 (M5); 24 hours; n=8, 7 | GSK2506104 (M3); 3 hours; n=8, 7 | GSK2506104 (M3); 12 hours; n=7, 7 | GSK2506104 (M3); 24 hours; n=6, 1 | GSK2531398 (M6); 3 hours; n=8, 7 | GSK2531398 (M6); 12 hours; n=7, 7 | GSK2531398 (M6); 24 hours; n=8, 7 | GSK2531401 (M13); 3 hours; n=8, 7 | GSK2531401 (M13); 12 hours; n=7, 7 | GSK2531401 (M13); 24 hours; n=5, 1 | |
| Part 2: Healthy Participants | 0.0032 | 0.1246 | NA | 0.3343 | 0.3174 | NA | 0.2857 | 0.2766 | 0.3387 | 0.2171 | 0.2191 | NA | 0.2938 | 0.2845 | 0.3016 | 0.2444 | 0.2346 | NA | 0.3569 | 0.3386 | 0.3845 |
| Part 2: Mild Hepatic Impairment Participants | 0.0134 | 0.1231 | NA | 0.3191 | 0.3305 | 0.4099 | 0.2762 | 0.2850 | 0.3116 | 0.2339 | 0.2483 | NA | 0.2904 | 0.2970 | 0.3267 | 0.2491 | 0.2500 | NA | 0.3595 | 0.3527 | 0.4154 |
8 reviews available for glycine and Liver Dysfunction
| Article | Year |
|---|---|
DETERMINATION OF RED BLOOD CELL LIFE SPAN.
Topics: Anemia; Carbon Isotopes; Chromium Isotopes; Erythrocytes; Glycine; Hemoglobins; Hemoglobins, Abnorma | 1964 |
PEDIATRIC ASPECTS OF THE PORPHYRIAS.
Topics: Blood Chemical Analysis; Child; Erythropoiesis; Feces; Genetics, Medical; Glycine; Humans; Liver Dis | 1964 |
The role of glycine in hepatic ischemia-reperfusion injury.
Topics: Animals; Glycine; Humans; Liver; Liver Diseases; Reperfusion Injury | 2006 |
Neurologic manifestations of acute porphyria.
Topics: Acute Disease; Aminolevulinic Acid; Animals; Central Nervous System; Depression; Electrophysiology; | 1982 |
[Biologic properties of lipoic acid].
Topics: Acquired Immunodeficiency Syndrome; Aging; Animals; Antioxidants; Cataract; Decarboxylation; Diabeti | 2002 |
Bile salts and the liver.
Topics: Acute Kidney Injury; Animals; Bile Acids and Salts; Biological Transport, Active; Cholesterol; Feedb | 1972 |
[Clinical study of arylamidases].
Topics: Adrenal Glands; Amidohydrolases; Bile; Biliary Tract Diseases; Glycine; Humans; Intestinal Mucosa; K | 1972 |
[Disturbances of metabolism in experimental porphyrias].
Topics: Alanine Transaminase; Animals; Glycine; Hemoglobins; Humans; Hypnotics and Sedatives; Levulinic Acid | 1969 |
6 trials available for glycine and Liver Dysfunction
| Article | Year |
|---|---|
Effect of Moderate Hepatic Impairment on the Pharmacokinetics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Topics: Administration, Oral; Aged; Area Under Curve; Fasting; Female; Glycine; Humans; Liver Diseases; Male | 2021 |
Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Boron Compounds; Female; Glycine; Humans; Live | 2016 |
No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Topics: Administration, Oral; Adult; Aged; Amidines; Anticoagulants; Area Under Curve; Azetidines; Benzylami | 2003 |
Abnormal glycine betaine content of the blood and urine of diabetic and renal patients.
Topics: Adult; Albuminuria; Betaine; Chromatography, High Pressure Liquid; Creatinine; Diabetes Mellitus; Fe | 1994 |
Glycine attenuates hepatocellular depression during early sepsis and reduces sepsis-induced mortality.
Topics: Analysis of Variance; Animals; Calcium; Cecum; Coloring Agents; Down-Regulation; Enzyme-Linked Immun | 2001 |
Quantification of hepatobiliary function as an integral part of imaging with technetium-99m-mebrofenin in health and disease.
Topics: Aniline Compounds; Biliary Tract; Biliary Tract Diseases; Bilirubin; Female; Glycine; Humans; Imino | 1991 |
80 other studies available for glycine and Liver Dysfunction
| Article | Year |
|---|---|
Altered bile acid glycine : taurine ratio in the progression of chronic liver disease.
Topics: Bile Acids and Salts; Case-Control Studies; Chronic Disease; Disease Progression; Female; Glycine; H | 2022 |
Pharmacokinetics of Daprodustat and Metabolites in Individuals with Normal and Impaired Hepatic Function.
Topics: Barbiturates; Female; Glycine; Humans; Liver Diseases; Male; Prolyl-Hydroxylase Inhibitors | 2022 |
Perinatal exposure to a glyphosate pesticide formulation induces offspring liver damage.
Topics: Animals; Antioxidants; Drinking Water; Female; Glycine; Glyphosate; Herbicides; Interleukin-6; Iron; | 2022 |
Elevated Levels of Toxic Bile Acids in Serum of Cystic Fibrosis Patients with
Topics: Bile Acids and Salts; Cholic Acid; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regula | 2022 |
Sivelestat sodium hydrate inhibits neutrophil migration to the vessel wall and suppresses hepatic ischemia-reperfusion injury.
Topics: Animals; Cell Adhesion; Chemotaxis, Leukocyte; Disease Models, Animal; Dose-Response Relationship, D | 2014 |
Propargylglycine aggravates liver damage in LPS-treated rats: Possible relation of nitrosative stress with the inhibition of H2S formation.
Topics: Alkynes; Amidohydrolases; Animals; Arginine; Aspartate Aminotransferases; Chromatography, High Press | 2014 |
Aqueous extract from Aconitum carmichaelii Debeaux reduces liver injury in rats via regulation of HMGB1/TLR4/NF-ΚB/caspase-3 and PCNA signaling pathways.
Topics: Aconitum; Animals; Caspase 3; Cysteine; Drug Combinations; Galactosamine; Glycine; Glycyrrhetinic Ac | 2016 |
Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Area Under Curve; Erythropoietin; Female; Glycine; Half- | 2016 |
Prolonged feeding with guanidinoacetate, a methyl group consumer, exacerbates ethanol-induced liver injury.
Topics: Alanine Transaminase; Amidinotransferases; Animals; Aspartate Aminotransferases; Body Weight; Calciu | 2016 |
A glyphosate-based herbicide induces histomorphological and protein expression changes in the liver of the female guppy Poecilia reticulata.
Topics: Animals; Chemical and Drug Induced Liver Injury; Female; Glycine; Glyphosate; Herbicides; Liver; Liv | 2017 |
Glycine attenuates endotoxin-induced liver injury by downregulating TLR4 signaling in Kupffer cells.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Down-Regulation; Fe | 2008 |
Dietary glycine blunts liver injury after bile duct ligation in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Calcium; Cells, Cultured; Chlorides; Cho | 2008 |
Fundamental efforts toward the development of a therapeutic cocktail with a manifold ameliorative effect on hepatic ischemia/reperfusion injury.
Topics: Alanine; Animals; Arginine; Chemotaxis, Leukocyte; Clinical Enzyme Tests; Drug Therapy, Combination; | 2009 |
Effects of gadolinium chloride and glycine on hepatic and pancreatic tissue damage in alcoholic pancreatitis.
Topics: Analysis of Variance; Animals; Ethanol; Gadolinium; Glycine; Glycine Agents; Liver; Liver Circulatio | 2010 |
Platelet adhesion in the sinusoid caused hepatic injury by neutrophils after hepatic ischemia reperfusion.
Topics: Animals; Blood Platelets; Cytokines; Glycine; Liver; Liver Circulation; Liver Diseases; Male; Neutro | 2010 |
Glycine pretreatment ameliorates liver injury after partial hepatectomy in the rat.
Topics: Alanine Transaminase; alpha-Tocopherol; Animals; Aspartate Aminotransferases; Drug Evaluation, Precl | 2010 |
Increase in future remnant liver function after preoperative portal vein embolization.
Topics: Adult; Aged; Aniline Compounds; Embolization, Therapeutic; Female; Glycine; Hepatectomy; Humans; Imi | 2011 |
Increase in future remnant liver function after preoperative portal vein embolization.
Topics: Adult; Aged; Aniline Compounds; Embolization, Therapeutic; Female; Glycine; Hepatectomy; Humans; Imi | 2011 |
Increase in future remnant liver function after preoperative portal vein embolization.
Topics: Adult; Aged; Aniline Compounds; Embolization, Therapeutic; Female; Glycine; Hepatectomy; Humans; Imi | 2011 |
Increase in future remnant liver function after preoperative portal vein embolization.
Topics: Adult; Aged; Aniline Compounds; Embolization, Therapeutic; Female; Glycine; Hepatectomy; Humans; Imi | 2011 |
Neutrophil elastase inhibitor attenuates lipopolysaccharide-induced hepatic microvascular dysfunction in mice.
Topics: Analysis of Variance; Animals; Benzoates; Cytokines; Disease Models, Animal; Drug Interactions; Glyc | 2002 |
Glycine modulates cytokine secretion, inhibits hepatic damage and improves survival in a model of endotoxemia in mice.
Topics: Adjuvants, Immunologic; Animals; CD4-Positive T-Lymphocytes; Cells, Cultured; Cytokines; Disease Mod | 2003 |
[Interaction of various amino acids and vitamin B12 in the prevention of nutritional hepatic steatosis in the rat].
Topics: Amino Acids; Animals; Corrinoids; Fatty Liver; Glycine; Glycine Agents; Liver Diseases; Rats; Trypto | 1955 |
[Behavior of blood glycine after intravenous load of sodium benzoate in normal persons and in persons with liver diseases. II].
Topics: Benzoates; Glycine; Humans; Liver Diseases; Liver Function Tests; Sodium Benzoate | 1957 |
[Thioctic acid and liver function. I. Influence of thioctic acid on the blood amino acid curve after intravenous loading with glycine in normal subjects and in liver disease patients].
Topics: Amino Acids; Digestion; Glycine; Glycine Agents; Humans; Liver Diseases; Thioctic Acid; Vitamin A; V | 1958 |
[Thioctic acid and hepatic function. II. Influence of thioctic acid-cocarboxylase association on amino-acidemic curve by endovenous administration of glycocoll in normal subjects and in liver patients].
Topics: Glycine; Glycine Agents; Humans; Liver Diseases; Thiamine Pyrophosphate; Thioctic Acid; Vitamin A; V | 1958 |
Studies on the determination of the human glycine pool.
Topics: Glycine; Humans; Liver Diseases; Metabolic Diseases | 1959 |
AMINO ACID INCORPORATION INTO PROTEIN BY LIVER MITOCHONDRIA FROM NEPHROTIC AND PARTIALLY HEPATECTOMIZED RATS.
Topics: Amino Acids; Carbon Isotopes; Glycine; Hepatectomy; Liver; Liver Diseases; Liver Regeneration; Mitoc | 1963 |
AMINO ACID INCORPORATION INTO PROTEIN OF HEPATIC TISSUE IN CLOUDY SWELLING.
Topics: Amino Acids; Carbon Isotopes; Glycine; Leucine; Liver; Liver Diseases; Proteins; Rats; Research | 1963 |
HEPATIC CUTANEOUS PORPHYRIA. RESPONSE OF A PATIENT TO TREATMENT WITH ADENOSINE-5-MONOPHOSPHATE.
Topics: Adenine Nucleotides; Adenosine; Blood Chemical Analysis; Glycine; Humans; Levulinic Acids; Liver Dis | 1964 |
[A STUDY OF THE FREE AMINO ACIDS IN THE SERUM OF LIVER DISEASES].
Topics: Alanine; Amino Acids; Ammonia; Animals; Arginine; Blood; Carbon Tetrachloride; Chemical and Drug Ind | 1964 |
[Multiple sclerosis; pathogenic considerations and therapeutic possibilities].
Topics: Glycine; Humans; Liver Diseases; Multiple Sclerosis | 1955 |
[Relation between fatty liver due to cystine and methionine and glycine].
Topics: Cystine; Fabaceae; Fatty Liver; Glycine; Humans; Liver Diseases; Methionine | 1962 |
Neutrophil elastase inhibitor prevents endotoxin-induced liver injury following experimental partial hepatectomy.
Topics: Animals; Chemical and Drug Induced Liver Injury; Endotoxins; Glycine; Hepatectomy; Humans; Leukocyte | 2007 |
Parameters obtained by hepatobiliary scintigraphy have significant correlation with biochemical factors early after liver transplantation.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Amyloid Neuropathies, Familial; Aniline Compounds; As | 2007 |
Stronger Neo-Minophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein.
Topics: Alanine Transaminase; Animals; Antioxidants; Carbon Tetrachloride; Chemical and Drug Induced Liver I | 2007 |
Protective effect of Sivelestat in a porcine hepatectomy model prepared using an intermittent Pringle method.
Topics: Animals; Aspartate Aminotransferases; Blood Pressure; Cell Line; Enzyme Inhibitors; Glycine; Heart R | 2008 |
Differential diagnostic value in hepatobiliary disease of serum conjugated bile acid concentrations and some routine liver tests assessed by discriminant analysis.
Topics: Adolescent; Adult; Aged; Alkaline Phosphatase; Aspartate Aminotransferases; Bile Acids and Salts; Bi | 1983 |
Work in progress: clinical evaluation of Tc-99m-trimethylbromo-IDA and Tc-99m-diisopropyl-IDA for hepatobiliary imaging.
Topics: Adult; Aniline Compounds; Biliary Tract; Biliary Tract Diseases; Drug Evaluation; Glycine; Humans; I | 1983 |
Fluorescence high-performance liquid chromatographic determination of free and conjugated bile acids in serum and bile using 1-bromoacetylpyrene as a pre-labeling reagent.
Topics: Bile; Bile Acids and Salts; Chromatography, High Pressure Liquid; Fluorescent Dyes; Glycine; Humans; | 1983 |
Hepatobiliary study. Left hepatic lobe herniation into the thorax.
Topics: Adolescent; Aniline Compounds; Female; Gallbladder Diseases; Glycine; Hernia; Hernia, Diaphragmatic, | 1994 |
The hot spot hepatobiliary scan in focal nodular hyperplasia.
Topics: Adult; Aniline Compounds; Biliary Tract; Female; Glycine; Humans; Imino Acids; Liver; Liver Diseases | 1993 |
Pan-sulfation of bile salts markedly increases hydrophilicity and essentially abolishes self- and hetero-association with lecithin.
Topics: Bile Acids and Salts; Cholestasis; Glycine; Humans; Hydrogen-Ion Concentration; Liver Diseases; Memb | 1993 |
Preliminary assessment of glycine conjugation of para-aminobenzoic acid as a quantitative test of liver function.
Topics: 4-Aminobenzoic Acid; Adolescent; Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Bil | 1995 |
Glycine conjugation of para-aminobenzoic acid (PABA): a quantitative test of liver function.
Topics: 4-Aminobenzoic Acid; Acute Disease; Adolescent; Aminohippuric Acids; Child; Child, Preschool; Chroni | 1995 |
Unusual appearance of viable liver on Tc-99m mebrofenin hepatobiliary imaging.
Topics: Aniline Compounds; Bile Ducts, Intrahepatic; Cholestasis, Extrahepatic; Cholestasis, Intrahepatic; C | 1997 |
Procedure guideline for hepatobiliary scintigraphy. Society of Nuclear Medicine.
Topics: Adult; Aniline Compounds; Biliary Tract; Biliary Tract Diseases; Child; Glycine; Humans; Imino Acids | 1997 |
ONO-5046, an elastase inhibitor, attenuates liver mitochondrial dysfunction after endotoxin.
Topics: Adenosine Diphosphate; Animals; Blood Pressure; Chemical and Drug Induced Liver Injury; Dose-Respons | 1998 |
Tri-iodothyronine and a deleted form of hepatocyte growth factor act synergistically to enhance liver proliferation and enable in vivo retroviral gene transfer via the peripheral venous system.
Topics: Animals; Cell Division; Genetic Therapy; Genetic Vectors; Glycine; Hepatocyte Growth Factor; Liver; | 2000 |
[Quantitative assay of metabolic rate of para-aminobenzoic acid combining glycine for the assessment of rabbit liver function].
Topics: 4-Aminobenzoic Acid; Animals; Galactosamine; Glycine; Liver; Liver Diseases; Liver Function Tests; M | 2001 |
Dietary glycine inhibits activation of nuclear factor kappa B and prevents liver injury in hemorrhagic shock in the rat.
Topics: Animals; Body Weight; Catalase; Dietary Supplements; Glutathione; Glutathione Peroxidase; Glycine; L | 2001 |
Cyclosporin A causes a hypermetabolic state and hypoxia in the liver: prevention by dietary glycine.
Topics: Animals; Body Weight; Calcium; Chemical and Drug Induced Liver Injury; Cyclosporine; Dietary Supplem | 2001 |
The role of IDA scintigraphy in the follow-up of liver disease in patients with cystic fibrosis.
Topics: Adolescent; Adult; Aniline Compounds; Child; Cystic Fibrosis; Female; Follow-Up Studies; Glycine; Hu | 2002 |
[Comparative studies on leucyl aminopeptidase (LAP) and glycyl aminopeptidase (GAP) in diseases of the liver and biliary tract. II. Isoenzymatic profile of LAP and GAP].
Topics: Aminopeptidases; Biliary Tract Diseases; Clinical Enzyme Tests; Glycine; Humans; Isoenzymes; Leucyl | 1977 |
Duodenal bile acid concentrations in fat malabsorption syndromes.
Topics: Adult; Bile Acids and Salts; Biliary Tract Diseases; Celiac Disease; Duodenum; Female; Food; Glycine | 1977 |
The origins and kinetics of bilirubin in dogs with hepatobiliary and haemolytic diseases.
Topics: Anemia, Hemolytic; Animals; Bilirubin; Carbon Radioisotopes; Dogs; Erythrocytes; Female; Glycine; He | 1992 |
Amino acid release from cerebral cortex in experimental acute liver failure, studied by in vivo cerebral cortex microdialysis.
Topics: Acute Disease; Amino Acids; Animals; Aspartic Acid; Cerebral Cortex; Dialysis; gamma-Aminobutyric Ac | 1992 |
Acute poisoning with a glyphosate-surfactant herbicide ('Roundup'): a review of 93 cases.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Cardiovascular Diseases; Central Nervous Sy | 1991 |
Excitatory and inhibitory amino acid neurotransmitters and ammonia metabolism in hepatic failure rats.
Topics: Ammonia; Animals; Aspartic Acid; Brain; Carbon Tetrachloride Poisoning; gamma-Aminobutyric Acid; Glu | 1985 |
Prevalence of the 281 (Gly----Glu) mutation in hepatoerythropoietic porphyria and porphyria cutanea tarda.
Topics: Carboxy-Lyases; DNA; Glutamates; Glutamic Acid; Glycine; Humans; Liver Diseases; Mutation; Nucleic A | 1988 |
Clinical evaluation of serum 3 beta-hydroxy-5-cholenoic acid in hepatobiliary diseases.
Topics: 3-Hydroxysteroid Dehydrogenases; Bile Acids and Salts; Bilirubin; Cholestasis, Extrahepatic; Cholest | 1986 |
Orthohydroxyhippuric (salicyluric) acid--its physiologic and clinical significance.
Topics: Anemia; Animals; Cattle; Dihydroxyphenylalanine; Dogs; Down Syndrome; Fever; Glycine; Humans; Hypert | 1974 |
Urea inhibition of lactate dehydrogenase. A convenient routine procedure.
Topics: Anemia; Buffers; Clinical Enzyme Tests; Glycine; Humans; Ischemia; L-Lactate Dehydrogenase; Liver; L | 1970 |
[Comparative studies on the catalytic activity of isoenzymes of alkaline phosphatase, using "conventional" and "optimized" test conditions (author's transl)].
Topics: Alkaline Phosphatase; Amino Alcohols; Analysis of Variance; Biliary Tract Diseases; Bone Diseases; B | 1974 |
Bile acid metabolism and hepatic disease following small bowel bypass for obesity.
Topics: Adult; Bile; Bile Acids and Salts; Bilirubin; Chenodeoxycholic Acid; Cholic Acids; Deoxycholic Acid; | 1974 |
Assessment of the 14C-glycocholic acid breath test.
Topics: Bacteria; Bacterial Infections; Bile Acids and Salts; Blind Loop Syndrome; Carbon Dioxide; Carbon Is | 1973 |
[A study on etiology and treatment of cataract].
Topics: Adult; Aged; Amino Acids; Animals; Cataract; Diabetes Complications; Female; Glycine; Humans; Hypopa | 1973 |
Influence of buffer conditions on the activities of some iso-enzymes of alkaline phosphatase in the serum.
Topics: Alkaline Phosphatase; Animals; Biliary Tract Diseases; Bone and Bones; Buffers; Cattle; Colorimetry; | 1973 |
Toxicity and metabolic effects of 3,4-dehydroproline in mice.
Topics: Amino Acids; Animals; Carbon Radioisotopes; Chemical and Drug Induced Liver Injury; Collagen; Female | 1973 |
Plasma amino acids in experimental acute hepatic failure and their relationship to brain tryptophan.
Topics: Acute Disease; Alanine; Amino Acids; Animals; Brain Chemistry; Disease Models, Animal; Glycine; Hepa | 1974 |
Serum peptidases in myocardial infarction.
Topics: Acyltransferases; Adult; Aged; Blood Protein Electrophoresis; Cholecystitis; Female; Glutamates; Gly | 1972 |
[Gamma-glutamyltranspeptidase determination].
Topics: Acyltransferases; Adult; Aged; Amides; Anilides; Colorimetry; Dipeptides; Female; Glutamates; Glycin | 1972 |
[A case of methylmalonic acid acidosis].
Topics: Acidosis; Amino Acid Metabolism, Inborn Errors; Female; Glycine; Humans; Infant Nutrition Disorders; | 1971 |
Abnormalities of fibrin stabilization in liver and kidney disease: a comparison of two different methods.
Topics: Acute Kidney Injury; Adolescent; Adult; Aged; Chronic Disease; Factor XIII; Female; Glycine; Hemorrh | 1969 |
Plasma fibrinogen: determination, normal values, physiopathologic shifts, and fluctuations.
Topics: Blood Coagulation; Blood Coagulation Disorders; Chemical Precipitation; Densitometry; Diabetes Melli | 1970 |
Serum bile acids in liver disease.
Topics: Adult; Aged; Bile Acids and Salts; Biliary Tract Diseases; Cholanes; Cholestasis; Colitis, Ulcerativ | 1971 |
[Influence of diet, glycine and alcohol on porphyrinuria in chronic hepatitic porphyria].
Topics: Adult; Biopsy; Diet; Ethanol; Fasting; Fatty Liver; Female; Glycine; Humans; Liver Diseases; Male; P | 1971 |
Chronic hepatic porphyria type C.
Topics: Adult; Ethanol; Fasting; Fatty Liver; Glycine; Humans; Liver; Liver Cirrhosis; Liver Diseases; Male; | 1971 |
The origins of bilirubin.
Topics: Anemia, Hypochromic; Animals; Bilirubin; Carbon Isotopes; Erythropoiesis; Glycine; Hematologic Disea | 1968 |
[On the behavior of the so-called leucine aminopeptidase (LAP) in the serum during the application of various substrates].
Topics: Adolescent; Adult; Aged; Animals; Aspartate Aminotransferases; Biliary Tract Diseases; Cholestasis; | 1968 |
Effect of dietary cholesterol on bile-acid composition of gall bladder bile from guinea pigs.
Topics: Anemia; Animals; Bile; Bile Acids and Salts; Cholesterol; Chromatography, Thin Layer; Colorimetry; D | 1969 |
[Measurement of the curve from the intravenous loading of glycine according to Bufano with ninhydrin photometric method].
Topics: Glycine; Humans; In Vitro Techniques; Kidney Diseases; Liver Diseases; Liver Function Tests; Photome | 1966 |
[On so-called "slight hepatic insufficiency" and its diagnosis].
Topics: Amino Acids; Bilirubin; Glycine; Humans; Liver Diseases; Liver Function Tests; Sulfobromophthalein | 1966 |